Nikolay Korokhov
Overview
Explore the profile of Nikolay Korokhov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jessup J, Kabbout M, Korokhov N, Joun A, Tollefson A, Wold W, et al.
Hum Vaccin Immunother
. 2019 Oct;
16(3):636-644.
PMID: 31584324
Treatments with cytotoxic agents or viruses may cause Immunogenic Cell Death (ICD) that immunize tumor-bearing hosts but do not cause complete regression of tumor. We postulate that combining two ICD...
2.
Mascarenhas J, Korokhov N, Burger L, Kassim A, Tuter J, Miller D, et al.
Biotechnol Bioeng
. 2016 Sep;
114(3):576-588.
PMID: 27642072
Contamination by the parvovirus minute virus of mice (MVM) remains a challenge in Chinese hamster ovary (CHO) biopharmaceutical production processes. Although infrequent, infection of a bioreactor can be catastrophic for...
3.
Matter M, Marquardt J, Andersen J, Quintavalle C, Korokhov N, Stauffer J, et al.
Hepatology
. 2016 Feb;
63(6):1888-99.
PMID: 26844528
Unlabelled: The majority of hepatocellular carcinoma develops in the background of chronic liver inflammation caused by viral hepatitis and alcoholic or nonalcoholic steatohepatitis. However, the impact of different types of...
4.
Williams B, Bhatia S, Adams L, Boling S, Carroll J, Li X, et al.
PLoS One
. 2012 Oct;
7(10):e46981.
PMID: 23056548
Human prostate tumor vaccine and gene therapy trials using ex vivo methods to prime dendritic cells (DCs) with prostate specific membrane antigen (PSMA) have been somewhat successful, but to date...
5.
Lemiale F, Asefa B, Ye D, Chen C, Korokhov N, Humeau L
Vaccine
. 2010 Mar;
28(8):1952-61.
PMID: 20188251
Recently developed viral-vectored HIV vaccine candidates, despite achieving high levels transgene expression and inducing high magnitude immune responses to HIV, have faced limitations related to anti-vector immunity. In contrast, lentiviral...
6.
Asefa B, Korokhov N, Lemiale F
Vaccine
. 2010 Jan;
28(20):3617-24.
PMID: 20051277
Viral vectors are considered as one of the major means for the induction of strong immune responses against recombinant antigens by genetic immunization. Among these, lentiviral vectors are particularly attractive...
7.
Thacker E, Nakayama M, Smith B, Bird R, Muminova Z, Strong T, et al.
Vaccine
. 2009 Sep;
27(50):7116-24.
PMID: 19786146
Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of...
8.
Agosto L, Yu J, Liszewski M, Baytop C, Korokhov N, Humeau L, et al.
J Virol
. 2009 Jun;
83(16):8153-62.
PMID: 19493998
Current gene transfer protocols for resting CD4(+) T cells include an activation step to enhance transduction efficiency. This step is performed because it is thought that resting cells are resistant...
9.
Lemiale F, Korokhov N
Vaccine
. 2009 Feb;
27(25-26):3443-9.
PMID: 19201386
HIV/AIDS has posed major challenges to the scientific community, both in terms of treatment and prevention. Current drug regimens, while efficacious, are expensive, inaccessible to major parts of the world,...
10.
Richardson M, Carroll R, Stremlau M, Korokhov N, Humeau L, Silvestri G, et al.
J Virol
. 2008 Sep;
82(22):11117-28.
PMID: 18768965
Rhesus TRIM5alpha (rhTRIM5alpha), but not human TRIM5alpha (huTRIM5alpha), potently inhibits human immunodeficiency virus (HIV) infection and is thus a potentially valuable therapeutic tool. Primary human CD4 T cells engineered to...